Advertisement

Current Hypertension Reports

, Volume 13, Issue 2, pp 158–162 | Cite as

Metabolic Syndrome, Androgens, and Hypertension

  • Mohadetheh Moulana
  • Roberta Lima
  • Jane F. Reckelhoff
Article

Abstract

Obesity is one of the constellation of factors that make up the definition of the metabolic syndrome. Metabolic syndrome is also associated with insulin resistance, dyslipidemia, hypertriglyceridemia, and type 2 diabetes mellitus. The presence of obesity and metabolic syndrome in men and women is also associated with increased risk of cardiovascular disease and hypertension. In men, obesity and metabolic syndrome are associated with reductions in testosterone levels. In women, obesity and metabolic syndrome are associated with increases in androgen levels. In men, reductions in androgen levels are associated with inflammation, and androgen supplements reduce inflammation. In women, increases in androgens are associated with increases in inflammatory cytokines, and reducing androgens reduces inflammation. This review discusses the possibility that the effects of androgens on metabolic syndrome and its sequelae may differ between males and females.

Keywords

Polycystic ovary syndrome Menopause Aging Inflammation Androgens Metabolic syndrome Postmenopausal hypertension Cardiovascular disease Testosterone 

Notes

Acknowledgments

The authors acknowledge the support of the National Institutes of Health RO1s HL66072 and HL69194 and PO1 HL51971.

Disclosure

No potential conflicts of interest relevant to this article were reported.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    Yach D, Stuckler D, Brownell KD. Epidemiologic and economic consequences of the global epidemics of obesity and diabetes. Nat Med. 2006;12:62–6.PubMedCrossRefGoogle Scholar
  2. 2.
    Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999–2008. JAMA. 2010;303:235–41.PubMedCrossRefGoogle Scholar
  3. 3.
    Tamler R. Diabetes, obesity and erectile dysfunction. Gender Medicine. 2009;6:4–16.PubMedCrossRefGoogle Scholar
  4. 4.
    Stanworth RD, Jones TH. Testosterone in obesity, metabolic syndrome and type 2 diabetes. Front Horm Res. 2009;37:74–90.PubMedCrossRefGoogle Scholar
  5. 5.
    Azziz R, Carmina E, Dewailly D, et al. Position statement: Criteria for defining polycystic ovary syndrome: An Androgen Excess Society guideline. J Clin Endocrinol Metab. 2006;91:4237–5.PubMedCrossRefGoogle Scholar
  6. 6.
    Laughlin GA, Barrett-Connor E, Kritz-Silverstein D, von Muhlen D. Hysterectomy, oophorectomy, and endogenous sex hormone levels in older women: the Rancho Bernardo Study. J Endocrinol Metabol. 2000;85:645–51.CrossRefGoogle Scholar
  7. 7.
    • Traish TM, Saad F, Feeley RJ, Guay A. The dark side of testosterone deficiency: III. Cardiovascular disease. J Androl. 2009;30:477–94. This is a concise review that discusses the known effects of androgens on various cardiovascular systems and hypertension.PubMedCrossRefGoogle Scholar
  8. 8.
    Malkin CJ, Channer KS, Jones TH. Testosterone and heart failure. Curr Opin Endocrinol Diabetes Obes. 2010;17:262–8.PubMedCrossRefGoogle Scholar
  9. 9.
    Carrero JJ, Qureshi AR, Parini P, et al. Low serum testosterone increases mortality risk among male dialysis patients. J Am Soc Nephrol. 2009;20:613–20.PubMedCrossRefGoogle Scholar
  10. 10.
    Shabsigh R, Arver K, Channer KS, et al. The triad of erectile dysfunction, hypogonadism and the metabolic syndrome. Int J Clin Prac. 2008;62:791–8.CrossRefGoogle Scholar
  11. 11.
    Allan CA, McLachlan RI. Androgens and obesity. Curr Opin Endocrinol Diabetes Obes. 2010;17:224–32.PubMedCrossRefGoogle Scholar
  12. 12.
    Traish AM, Kypreos KE. Testosterone and cardiovascular disease: An old idea with modern clinical implications. Atherosclerosis 2010 Sep 22 (Epub ahead of print).Google Scholar
  13. 13.
    Akishita M, Fukai S, Hashimoto M, et al. Association of low testosterone with metabolic syndrome and its components in middle-aged Japanese men. Hypertens Res. 2010;33(6):587–91.PubMedCrossRefGoogle Scholar
  14. 14.
    Maggio M, Laurentiani F, Ceda GP, et al. Relationship between low levels of anabolic hormones and 6-year mortality in older men: the aging in the Chianti Area (InCHIANTI) study. Arch Intern Med. 2007;167:2249–54.PubMedCrossRefGoogle Scholar
  15. 15.
    Khaw K, Dowsett M, Folkerd E, et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) prospective population study. Circ. 2007;116:2694–701.CrossRefGoogle Scholar
  16. 16.
    Whitaker EM, Shaw MA, Hervey GR. Plasma oestradiol-17 beta and testosterone concentrations as possible causes of the infertility of congenitally obese Zucker rats. J Endocrinol. 1983;99:485–90.PubMedCrossRefGoogle Scholar
  17. 17.
    Hill JW, Elias CF, Williams KW, et al. Direct insulin and leptin action on pro-opiomelanocortin neurons is required for normal glucose homeostasis and fertility. Cell Metab. 2010;11:286–97.PubMedCrossRefGoogle Scholar
  18. 18.
    Perez-Torres I, Roque P, El Hafidi M, et al. Association of renal damage and oxidative stress in a rat model of metabolic syndrome. Influence of gender. Free Rad Biol Med. 2009;43:761–71.Google Scholar
  19. 19.
    Chakrabarti SK, Wen Y, Dobrian AD, et al. Evidence for activation of inflammatory lipoxygenase pathways in visceral adipose tissue of obese Zucker rats. Am J Physiol Endocrinol Metab. 2011;300(1):E175–87.PubMedCrossRefGoogle Scholar
  20. 20.
    Malkin CJ, Pugh PJ, Jones RD, et al. The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. J Clin Endocrin Metab. 2004;89:3313–8.CrossRefGoogle Scholar
  21. 21.
    Svartberg J, von Muhlen D, Sundsfjord J, Jorde R. Wait circumference and testosterone levels in community dwelling men. The Tromso study. Eur J Epidemiol. 2004;19:657–63.PubMedCrossRefGoogle Scholar
  22. 22.
    Neilsen TL, Hagen C, Wraae K, et al. Visceral and subcutaneous adipose tissue assessed by magnetic resonance imaging in relation to circulating androgens, sex hormone binding globulin, and luteinizing hormone in young men. J Clin Endocrin Metab. 2007;92:2696–705.CrossRefGoogle Scholar
  23. 23.
    Vermeulen A, Kaufman JM, Deslypere JP, Thomas G. Attenuated luteinizing hormone (LH) pulse amplitude but normal LH pulse frequency, and its relation to plasma androgens in hypogonadism of obese men. J Clin Endocrin Metab. 1993;76:1140–6.CrossRefGoogle Scholar
  24. 24.
    Giagulli VA, Kaufman JM, Vermeulen A. Pathogenesis of the decreased androgen levels in obese men. J Clin Endocrin Metab. 1994;79:997–1000.CrossRefGoogle Scholar
  25. 25.
    Isidori AM, Caprio M, Strollo F, et al. Leptin and androgens in male obesity: evidence for leptin contribution to reduced androgen levels. J Clin Endocrin Metab. 1999;84:3673–80.CrossRefGoogle Scholar
  26. 26.
    • Kapoor D, Channer KS, Jones TH. Rosiglitazone increases bioactive testosterone and reduces waist circumference in hypogonadal men with type 2 diabetes. Diab Vasc Dis Res. 2008;5:135–7. These authors describe studies in which obese men were given a thiazolidinedione, rosiglitazone, a PPARγ agonist, to improve insulin sensitivity. The drug also increases serum testosterone levels.PubMedCrossRefGoogle Scholar
  27. 27.
    Olivares A, Mendez JP, Zambrano E, et al. Reproductive axis function and gonadotropin microheterogeneity in a male rat model of diet-induced obesity. Gen Com Endocrinol. 2010;166:356–64.CrossRefGoogle Scholar
  28. 28.
    Cattaneo L, De Gennaro Colonna V, Zoli M, et al. Characterization of the hypothalamo-pituitary-IGF-1 axis in rats made obese by overfeeding. J Endocrinol. 1996;148:347–53.PubMedCrossRefGoogle Scholar
  29. 29.
    Cano P, Jimenez-Ortega V, Larrad A, et al. Effect of a high-fat diet on 24-h pattern of circulating levels of prolactin, luteinizing hormone and glucose, and pineal melatonin content, in rats. Endocrine. 2008;33:118–25.PubMedCrossRefGoogle Scholar
  30. 30.
    Ikeda Y, Aihara K, Akaike M, et al. Androgen receptor counteracts Doxorubicin-induced cardiotoxicity in male mice. Mol Endocrinol. 2010;24:1338–48.PubMedCrossRefGoogle Scholar
  31. 31.
    Sieveking DP, Lim P, Chow RW, et al. A sex specific role for androgens in angiogenesis. J Exp Med. 2010;207:345–52.PubMedCrossRefGoogle Scholar
  32. 32.
    Mah PM, Wittert GA. Obesity and testicular function. Molec Cell Endocrinol. 2010;316:180–6.PubMedCrossRefGoogle Scholar
  33. 33.
    Marin P, Holmang S, Gustafsson C, et al. Androgen treatment of abdominally obese men. Obesity Res. 1993;1:245–51.Google Scholar
  34. 34.
    Zitzmann M, Nieschlag E. Androgen receptor gene CAG repeat length and body mass index modulate the safety of long term intramuscular testosterone undecanoate therapy in hypogonadal men. J Clin Endocrin Metab. 2007;92:3844–53.CrossRefGoogle Scholar
  35. 35.
    Reckelhoff JF. Gender differences in the regulation of blood pressure. Hypertension. 2001;37:1199–208.PubMedGoogle Scholar
  36. 36.
    Reckelhoff JF, Zhang H, Granger JP. Testosterone exacerbates hypertension and reduces pressure-natriuresis in male spontaneously hypertensive rats. Hypertension. 1998;31:435–9.PubMedGoogle Scholar
  37. 37.
    Yanes LL, Iliescu R, Sartori-Valinotti JC, et al. Testosterone-dependent hypertension and upregulation of intrarenal angiotensinogen in Dahl salt-sensitive rats. Am J Physiol Reg Integr Comp Physiol. 2009;296:F771–9.Google Scholar
  38. 38.
    Schultheiss D, Machtens S, Jonas U. Review article: Testosterone therapy in the ageing male: What about the prostate? Andrologia. 2004;36:355–65.PubMedCrossRefGoogle Scholar
  39. 39.
    Mazer NA. A novel spreadsheet method for calculating free serum concentrations of testosterone, dihydrotestosterone, estradiol, sterone, and cortisol: with illustrative examples from male and female populations. Steroids. 2009;74:512–9.PubMedCrossRefGoogle Scholar
  40. 40.
    Harvie MN, Pegington M, Mattson MP, et al. The effects of intermittent or continuous energy restriction on weight loss and metabolic disease risk markers: a randomized trial in young overweight women. Int J Obes (Lond) 2010 Oct 5 (Epub ahead of print).Google Scholar
  41. 41.
    Diamanti-Kandarakis E. Polycystic ovarian syndrome; pathophysiology, molecular aspects and clinical implications. Exp Rev Mol Med. 2008;10:1–21.CrossRefGoogle Scholar
  42. 42.
    Diamanti-Kandarakis E. Insulin resistance in PCOS. Endocrine. 2006;30:13–7.PubMedCrossRefGoogle Scholar
  43. 43.
    Sahin Y, Unluhizarci K, Yilmazsoy A, et al. The effects of metformin on metabolic and cardiovascular risk factors in nonobese women with polycystic ovary syndrome. Clin Endocrinol. 2007;67:904–8.CrossRefGoogle Scholar
  44. 44.
    Manneras L, Cajander S, Holmang A, et al. A new rat model exhibiting both ovarian and metabolic characteristics of polycystic ovary syndrome. Endocrinol. 2007;148:3781–91.CrossRefGoogle Scholar
  45. 45.
    Baba T, Endo T, Honnma H, et al. Association between polycystic ovary syndrome and female-to-male transsexuality. Hum Reprod. 2006;22:1011–6.PubMedCrossRefGoogle Scholar
  46. 46.
    • Ho SC, Wu S, Chen SG, Sham A. Menopausal transition and changes of body composition: a prospective study in Chinese perimenopausal women. Int J Obesity. 2010;34:1265–74. This study showed that with menopause transition, in the absence of any weight gain, the fat deposition in women changes from subcutaneous to visceral. This study supports a previous study [48].CrossRefGoogle Scholar
  47. 47.
    Ozbey N, Sencer E, Molvalillar S, Orhan Y. Body fat distribution and cardiovascular disease risk factors in pre- and postmenopausal obese women with similar BMI. Endocrinol J. 2002;49:503–9.Google Scholar
  48. 48.
    Nedungadi TP, Clegg DJ. Sexual dimorphism in body fat distribution and risk for cardiovascular diseases. J Cardiovasc Transl Res. 2009;2:321–7.PubMedCrossRefGoogle Scholar
  49. 49.
    Reckelhoff JF, Fortepiani LA. Novel mechanisms responsible for postmenopausal hypertension. Hypertension. 2004;43:918–23.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Mohadetheh Moulana
    • 1
  • Roberta Lima
    • 1
  • Jane F. Reckelhoff
    • 1
  1. 1.Women’s Health Research CenterUniversity of Mississippi Medical CenterJacksonUSA

Personalised recommendations